Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344797 | 1.00 | HPGD (0.48) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL1279722 | 1.00 | HPGD (0.48) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL22731686 | 0.91 | MEN1 (0.51) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL25467053 | 0.91 | MEN1 (0.51) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL4147298 | 0.91 | MEN1 (0.51) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL4402979 | 0.90 | HPGD (0.54) | HPGDRECQLEPHX1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL27912903 | 0.89 | HPGD (0.53) | HPGDRECQLEPHX1MAPTALDH1A1 | |
| SCHEMBL6915624 | 0.86 | NR1H2 (0.50) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL35457 | 0.85 | HPGD (0.49) | HPGDRECQLEPHX1MAPTMEN1 | |
| SCHEMBL935410 | 0.85 | HPGD (0.49) | HPGDRECQLEPHX1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246936-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2024-07-25 | — | — | US | claimed |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. | 2023-09-21 | — | — | US | claimed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | claimed |
| EP-3279195-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Oyster Point Pharma, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| US-20160046609-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | CATALYST BIOSCIENCES, INC. | 2016-02-18 | — | — | US | claimed |
| EP-2358670-B1 | A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor | TARGACEPT INC (US) | 2012-10-24 | — | — | EP | claimed |
| US-8153821-B2 | Compounds | TARGACEPT, INC. (US) | 2012-04-10 | — | — | US | claimed |
| US-20110269975-A1 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-20240246936-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2024-07-25 | — | — | US | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010147938-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | HPGD 1449/4885RECQL 900/4885EPHX1 1172/4885 |
| US-20240246936-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, NUDT5, DHPS | HPGD 661/4885RECQL 991/4885EPHX1 959/4885 |
| US-20110269975-A1 | NOVEL COMPOUNDS | CHRNB2, CHRNA2, CHRNA5 | HPGD 2489/4885RECQL 3461/4885EPHX1 1094/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | HPGD 223/4885RECQL 977/4885EPHX1 511/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | HPGD 1182/4885RECQL 4623/4885EPHX1 2703/4885 |
| US-20160046609-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | HPGD 735/4885RECQL 1304/4885EPHX1 1217/4885 |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | HPGD 739/4885RECQL 1157/4885EPHX1 1192/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | HPGD 739/4885RECQL 1157/4885EPHX1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.